Mehta Analysis: Race To Harness Data Will Revolutionize PBM System
Executive Summary
Data and intelligence will drive revolutionary changes in healthcare, and today's power brokers will need to adapt. Viren Mehta, founding partner of Mehta Partners LLC, considers how business consolidation in the complex US pharma market reflects the race to tap as yet under-exploited data troves, and how the resulting exploitation of those data may benefit a broader set of stakeholders.
You may also be interested in...
PBM Controls Coming To Medical Benefit Drugs? Express Scripts Acquisition Offers Platform
Express Scripts' plan to purchase medical benefits management company eviCore may give the PBM an opportunity to bring new pricing pressures to the medical benefit drug space.
CVS Point-Of-Sale Rebate Program Adopted By 'Several' Payers
Manufacturer rebates can be used to reduce patient cost sharing at point of sale under the PBM's program. There is growing interest in the idea as a solution to lowering drug costs, but the practice could drive up insurance premiums.
Pharma And Intermediaries Split Money Spent On Drugs, Study Shows
For every $100 spent at retail pharmacies, $41 accrues to the manufacturer and $41 accrues to intermediaries in the distribution system, according to a new study on US prescription drug spending, though drug manufacturers hold onto more profit.